This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
CureVac（CVAC）株式概要
CureVac N.V.はバイオ医薬品会社で、メッセンジャー・リボ核酸（mRNA）に基づく様々な革新的医薬品の開発に注力している。 詳細
CVAC Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CureVac N.V. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$4.13 |
| 52週高値 | US$5.72 |
| 52週安値 | US$2.48 |
| ベータ | 1.77 |
| 1ヶ月の変化 | -21.78% |
| 3ヶ月変化 | -22.80% |
| 1年変化 | 50.18% |
| 3年間の変化 | -38.17% |
| 5年間の変化 | -95.92% |
| IPOからの変化 | -92.61% |
最新ニュース
Recent updates
分析記事 • Jun 15
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise
Despite an already strong run, CureVac N.V. ( NASDAQ:CVAC ) shares have been powering on, with a gain of 50% in the...分析記事 • May 27
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business
CureVac N.V. ( NASDAQ:CVAC ) recently posted some strong earnings, and the market responded positively. We did some...
新しいナラティブ • May 06
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.分析記事 • May 01
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth
Those holding CureVac N.V. ( NASDAQ:CVAC ) shares would be relieved that the share price has rebounded 31% in the last...Seeking Alpha • Mar 28
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Summary CureVac N.V.'s restructuring deal with GSK and workforce reduction suggest financial struggles, with net losses reported from 2020-2023; however, the GSK deal secures funding until 2028. CVAC stock received a boost yesterday after winning a key patent dispute against BioNTech, potentially leading to significant damages if infringement is confirmed in 2025. Despite the legal win, CureVac's pipeline remains weak, with only one wholly-owned asset in clinical development, raising concerns about its long-term viability. Upgrading CureVac stock from "Sell" to "Hold" due to the potential financial windfall from the patent dispute, though fundamental issues remain unresolved. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Summary CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025. Financially strong, with $208.8M in cash plus additional funds of $412.53M from GlaxoSmithKline agreement being redone; the Company believes that it has enough cash on hand to fund operations into 2028. Read the full article on Seeking Alpha分析記事 • Jan 04
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%
CureVac N.V. ( NASDAQ:CVAC ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Seeking Alpha • Oct 08
CureVac: Back To Square One
Summary Today, we're circling back to a development company called CureVac N.V. The company recently agreed to a deal with GSK plc, that involved a huge upfront payment, as well as potential milestone payouts and royalties. That left CureVac with a huge amount of cash on its balance sheet but pushed its pipeline back to very early-stage development. Read the full article on Seeking Alpha分析記事 • Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
It's not a stretch to say that CureVac N.V.'s ( NASDAQ:CVAC ) price-to-sales (or "P/S") ratio of 10.6x right now seems...分析記事 • Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Key Insights The projected fair value for CureVac is US$6.64 based on 2 Stage Free Cash Flow to Equity Current share...分析記事 • Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Jul 04
CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Summary CureVac's share price has plummeted over 90% in the past five years due to vaccine efficacy issues and legal disputes. The mRNA specialist was unable to develop a successful COVID vaccine, unlike rivals Moderna and BioNTech. GSK's $400m purchase of CureVac's infectious disease vaccine candidates, announced yesterday, provides a financial lifeline with milestones, and royalties pledged >$1bn. Despite the deal, CureVac still faces challenges in catching up to competitors like Moderna and BioNTech, making a "sell" recommendation appropriate at this time, in my view. Read the full article on Seeking Alpha分析記事 • Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
CureVac N.V. ( NASDAQ:CVAC ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Mar 08
CureVac: No Momentum In Sight
Summary CureVac faces challenges as a German court invalidates one of their key mRNA technology patents, raising concerns about their ability to compete in the mRNA space. The invalidated patent relates to an invention that many argue was not a genuine "invention" as the concepts and technologies were already well-known in the scientific community. CureVac's future prospects rely heavily on their partnerships, such as their joint effort with GSK for influenza and COVID vaccines, and their RNA Printer technology for point-of-care production of RNA therapeutics. Read the full article on Seeking Alpha分析記事 • Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
One thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a...分析記事 • Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Key Insights The projected fair value for CureVac is US$19.46 based on 2 Stage Free Cash Flow to Equity CureVac is...分析記事 • May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
The latest analyst coverage could presage a bad day for CureVac N.V. ( NASDAQ:CVAC ), with the analysts making...分析記事 • Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
The analysts might have been a bit too bullish on CureVac N.V. ( NASDAQ:CVAC ), given that the company fell short of...分析記事 • Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Key Insights CureVac's estimated fair value is €15.4 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Aug 18
CureVac BV reports Q2 results
CureVac BV press release (NASDAQ:CVAC): Q2 Pre-tax loss of €57.6M Revenue of €20.1M (-10.3% Y/Y). Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program Shares +1.37% PM.Seeking Alpha • Jul 05
CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
German biotech CureVac N.V. (NASDAQ:CVAC) announced on Tuesday that the company filed a lawsuit in Germany over the infringement of certain intellectual property rights related to the COVID-19 vaccine developed by its local rival BioNTech (BNTX) and U.S. pharma giant Pfizer (PFE). The case was filed in the German Regional Court in Düsseldorf against BioNTech (BNTX) and two of its subsidiaries, CureVac (CVAC) said, noting it would fair compensation for the alleged violations. While CureVac (CVAC) has added ~1%, both BioNTech (BNTX) and Pfizer (PFE) have lost ~1% in the pre-market so far. However, the company said that it would not seek an injunction or resort to a legal action that could disrupt the production and sales of the blockbuster vaccine. The IP rights titled EP 1 857 122 B1, DE 20 2015 009 961 U1 relate to the development of mRNA, the compound behind the Pfizer (PFE)/ BioNTech (BNTX) COVID-19 vaccine.分析記事 • May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
Celebrations may be in order for CureVac N.V. ( NASDAQ:CVAC ) shareholders, with the analysts delivering a significant...分析記事 • Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...Seeking Alpha • Sep 01
CureVac: Wait For Concrete News Before Investing
In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines. However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection. Following the August 31 update on CVnCoV, the biotech still makes for an investment case as it is developing a second generation vaccine and is also diversified on cancer cures. The cash position is also good. However, in view of past deceptions around efficacy, it is better to wait for concrete news before purchasing the stock.分析記事 • Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...株主還元
| CVAC | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -19.2% | -1.6% | -0.8% |
| 1Y | 50.2% | 34.4% | 27.1% |
業界別リターン: CVAC過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: CVAC過去 1 年間で27.1 % の収益を上げたUS市場を上回りました。
価格変動
| CVAC volatility | |
|---|---|
| CVAC Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CVAC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CVACの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2000 | 904 | Alexander Zehnder | www.curevac.com |
CureVac N.V.はバイオ医薬品会社で、メッセンジャーリボ核酸（mRNA）に基づく様々な革新的医薬品の開発に注力している。同社のポートフォリオには、予防ワクチン、腫瘍学、分子治療における様々な疾患適応の臨床および前臨床候補が含まれる。また、同社の技術を活用し、治療用タンパク質の産生を刺激するために最適化されたmRNAを提供し、核、細胞質、細胞小器官、細胞膜において特定のタンパク質を産生または分泌するようヒト細胞に指示する。また、mRNAワクチンや治療薬を製造するための小型化、統合化、高度自動化プロセスである「RNAプリンター」を提供している。さらに、尿路病原性大腸菌（UPEC）を標的とした尿路感染症に対処する予防ワクチンのリード候補、SARS-CoV-2に対する第2相臨床試験中のワクチン候補CV0601およびCV0701、がん領域における既製および完全個別化がん精密免疫療法用ワクチン、がん治療用CVGBMを開発している。さらに、SARS-CoV-2亜種を標的とするmRNAワクチン、非小細胞肺扁平上皮がんを標的とする抗原がん精密免疫療法候補、外科的に切除されたMGMT非メチル化膠芽腫または膠芽腫の分子シグネチャーを持つ星細胞腫患者を対象に試験される抗原がん精密免疫療法候補CVGBMを開発、製造、商品化している。CureVac N.V.は2000年に設立され、ドイツのテュービンゲンに本社を置いている。
CureVac N.V. 基礎のまとめ
| CVAC 基礎統計学 | |
|---|---|
| 時価総額 | US$1.09b |
| 収益（TTM） | US$151.26m |
| 売上高(TTM) | US$83.06m |
6.1x
PER（株価収益率11.2x
P/SレシオCVAC は割高か？
公正価値と評価分析を参照収益と収入
| CVAC 損益計算書（TTM） | |
|---|---|
| 収益 | €70.74m |
| 売上原価 | €4.75m |
| 売上総利益 | €65.99m |
| その他の費用 | -€62.83m |
| 収益 | €128.82m |
直近の収益報告
Sep 30, 2025
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.57 |
| グロス・マージン | 93.29% |
| 純利益率 | 182.11% |
| 有利子負債／自己資本比率 | 0% |
CVAC の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2025/12/17 13:13 |
| 終値 | 2025/12/17 00:00 |
| 収益 | 2025/09/30 |
| 年間収益 | 2024/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
CureVac N.V. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Eun Kyung Yang | Jefferies LLC |
| Roger Song | Jefferies LLC |